Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.07
(-1.75%)
SEK 0.07
(-1.75%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 90.74 Million SEK | 5720.4% |
| 2022 | 1.55 Million SEK | -13.77% |
| 2021 | 1.8 Million SEK | -31.64% |
| 2020 | 2.64 Million SEK | -21.23% |
| 2019 | 3.35 Million SEK | -22.62% |
| 2018 | 4.33 Million SEK | -25.05% |
| 2017 | 5.78 Million SEK | -9.63% |
| 2016 | 6.4 Million SEK | -11.41% |
| 2015 | 7.23 Million SEK | 0.0% |
| 2014 | - SEK | -100.0% |
| 2013 | 7142.00 SEK | -80.0% |
| 2012 | 35.71 Thousand SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 92.76 Million SEK | -1.46% |
| 2024 Q1 | 94.13 Million SEK | 6338.92% |
| 2023 Q4 | 90.74 Million SEK | -3.73% |
| 2023 Q3 | 94.26 Million SEK | -2.56% |
| 2023 Q1 | 92.61 Million SEK | 5840.54% |
| 2023 Q2 | 96.73 Million SEK | 4.45% |
| 2023 FY | 90.74 Million SEK | 5720.4% |
| 2022 FY | 1.55 Million SEK | -13.77% |
| 2022 Q4 | 1.55 Million SEK | -98.26% |
| 2022 Q3 | 89.37 Million SEK | 6038.67% |
| 2022 Q2 | 1.45 Million SEK | -7.85% |
| 2022 Q1 | 1.58 Million SEK | -12.61% |
| 2021 Q2 | 2.06 Million SEK | -10.97% |
| 2021 Q3 | 1.96 Million SEK | -4.9% |
| 2021 FY | 1.8 Million SEK | -31.64% |
| 2021 Q1 | 2.31 Million SEK | -12.48% |
| 2021 Q4 | 1.8 Million SEK | -7.76% |
| 2020 Q3 | 2.97 Million SEK | -4.06% |
| 2020 Q2 | 3.1 Million SEK | -0.77% |
| 2020 FY | 2.64 Million SEK | -21.23% |
| 2020 Q4 | 2.64 Million SEK | -11.09% |
| 2020 Q1 | 3.12 Million SEK | -6.94% |
| 2019 Q3 | 6.05 Million SEK | 50.24% |
| 2019 FY | 3.35 Million SEK | -22.62% |
| 2019 Q4 | 3.35 Million SEK | -44.55% |
| 2019 Q2 | 4.03 Million SEK | -6.58% |
| 2019 Q1 | 4.31 Million SEK | -0.56% |
| 2018 Q4 | 4.33 Million SEK | -3.27% |
| 2018 FY | 4.33 Million SEK | -25.05% |
| 2018 Q1 | 5.79 Million SEK | 0.0% |
| 2018 Q2 | 5.79 Million SEK | 0.0% |
| 2018 Q3 | 4.48 Million SEK | -22.52% |
| 2017 Q4 | 5.78 Million SEK | -9.63% |
| 2017 FY | 5.78 Million SEK | -9.63% |
| 2017 Q1 | 6.4 Million SEK | -0.0% |
| 2017 Q2 | 6.4 Million SEK | 0.0% |
| 2017 Q3 | 6.4 Million SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2016 FY | 6.4 Million SEK | -11.41% |
| 2016 Q1 | - SEK | -100.0% |
| 2016 Q4 | 6.4 Million SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2015 Q4 | 7.23 Million SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | 7.23 Million SEK | 0.0% |
| 2014 FY | - SEK | -100.0% |
| 2013 FY | 7142.00 SEK | -80.0% |
| 2012 FY | 35.71 Thousand SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 7.51 Million SEK | -1107.291% |
| Ziccum AB (publ) | 286 Thousand SEK | -31627.273% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 2.15 Million SEK | -4116.543% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 850 Thousand SEK | -10575.294% |
| Genovis AB (publ.) | 74.8 Million SEK | -21.297% |
| Intervacc AB (publ) | 142 Thousand SEK | -63801.408% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | 3 Million SEK | -2924.667% |
| Magle Chemoswed Holding AB (publ) | 32.58 Million SEK | -178.497% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 65.23 Million SEK | -39.091% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 4.29 Million SEK | -2012.197% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -21300.943% |
| Egetis Therapeutics AB (publ) | 103.4 Million SEK | 12.244% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -8974.0% |
| Calliditas Therapeutics AB (publ) | 939.5 Million SEK | 90.342% |
| Camurus AB (publ) | 13.61 Million SEK | -566.569% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 24.51 Million SEK | -270.201% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 844.9 Million SEK | 89.26% |
| Cyxone AB (publ) | 74 Thousand SEK | -122521.622% |
| ExpreS2ion Biotech Holding AB (publ) | 1.43 Million SEK | -6218.942% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 31.94 Million SEK | -184.033% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 136 Thousand SEK | -66620.588% |
| SynAct Pharma AB | 58 Thousand SEK | -156348.276% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -10575.294% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -5052.754% |
| BioInvent International AB (publ) | 14.53 Million SEK | -524.286% |
| Alzinova AB (publ) | 800 Thousand SEK | -11242.5% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 14.788% |
| Pila Pharma AB (publ) | - SEK | -Infinity% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Diamyd Medical AB (publ) | 30.67 Million SEK | -195.84% |
| Xbrane Biopharma AB (publ) | 112.89 Million SEK | 19.626% |
| Ascelia Pharma AB (publ) | 176 Thousand SEK | -51456.818% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |